Canadian TIA Score Versus ABCD2 Score in Risk Stratification of Transient Ischemic Attack (TIA)
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Dec 1, 2024
Trial Information
Current as of May 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two scoring systems used to evaluate the risk of stroke after a Transient Ischemic Attack (TIA), which is a temporary episode that can increase the risk of a full-blown stroke. The study will look at the Canadian TIA score to see if it is better than the ABCD2 score at predicting which patients are more likely to have complications, like a stroke, within the first 7 days and again at 90 days after the TIA. The goal is to improve patient care by identifying those who need more aggressive treatment right after their TIA.
If you are an adult who has been diagnosed with a TIA and are visiting the emergency department, you may be eligible to participate in this study. Over about two years, the researchers will enroll around 800 patients. Participation is simple: when you arrive at the emergency department, you will answer some questions that will take about a minute. Then, 7 days and 90 days later, you will receive a phone call to answer a quick survey about your health. This study is important because it could lead to better ways to manage patients at risk of stroke following a TIA.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • all patients presenting to the emergency department with a diagnosis of TIA
- • all adult patients
- • all patients who have signed the informed consent
- Exclusion Criteria:
- • none
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Veronica Salvatore, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported